Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

INTRODUCTION: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional therapy. In the RCTs, approximately 40% of patients treated with the approved...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Baraf, Herbert SB, Becker, Michael A, Gutierrez-Urena, Sergio R, Treadwell, Edward L, Vazquez-Mellado, Janitzia, Rehrig, Claudia D, Ottery, Faith D, Sundy, John S, Yood, Robert A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979037/
https://ncbi.nlm.nih.gov/pubmed/24286509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4318
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller